Clinical trials: Embryonal Neoplasm
Retinoblastoma, Wounds and Injury
Attention to Retinoblastoma Diagnosed in the Trauma Setting
To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
- Trial name
- NCT03764930
- Testing
- Unsuspected Retinoblastoma
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Medulloblastoma, Astrocytoma, Grade III
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
This is a safety (Phase 1) trial using mebendazole for recurrent pediatric brain cancers that include medulloblastoma and high grade glioma, that are no longing responding to standard therapies.
- Conditions
- Medulloblastoma, Astrocytoma, Grade III, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02644291
- Testing
- Mebendazole
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neuroendocrine Tumors
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan, instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor.
- Trial name
- NCT02358018
- Testing
- 68Ga-DOTATOC PET/CT Scan
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neurofibromatosis Type 2, Severe Profound Sensorineural Hearing Loss
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
The Nucleus 24 Auditory Brainstem Implant (ABI) is the only FDA approved device for restoration of meaningful hearing in Neurofibromatosis Type 2 (NF2) patients.
- Trial name
- NCT02589912
- Testing
- Nucleus Profile ABI541 Auditory Brainstem Implant
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with leucovorin and fluorouracil in treating young patients with advanced solid tumors.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00281944
- Testing
- oxaliplatin, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.
- Trial name
- NCT02970981
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- NYU Langone Health
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Glioma, Rhabdomyosarcoma
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
This study proposes to treat patients with the combination of erlotinib and temozolomide. Patients with relapsed, recurrent, refractory, or high risk malignancies whose tumors possess a non-synonymous mutation in EGFR, ERBB2, or…
- Conditions
- Glioma, Rhabdomyosarcoma, Osteosarcoma, Medulloblastoma
- Trial name
- NCT02689336
- Testing
- Erlotinib, Temozolomide
- Sponsor
- Washington University School of Medicine
Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas
Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor. Focused Ultrasound (FUS) using microbubbles and neuro-navigator-controlled sonication is a non-invasive method of temporarily opening…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- NCT04804709
- Testing
- Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Gestational Trophoblastic Neoplasia
Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy
- Trial name
- NCT03703271
- Testing
- Methotrexate, hysteroscopic repeat curettage
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Neuroblastoma
Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma
There is currently no curative treatment for children with relapsed/refractory neuroblastoma, and for these children the 5 year survival rate is <10%. As such, new therapeutic approaches are needed to treat these children.
- Trial name
- NCT00486564
- Testing
- Nifurtimox
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Vermont
Neuroectodermal Tumor, Primitive, Neuroepithelioma
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to…
- Conditions
- Neuroectodermal Tumor, Primitive, Neuroepithelioma, Osteosarcoma, Sarcoma
- Trial name
- NCT00001209
- Testing
- vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Vestibular Schwannoma, Acoustic Neuroma
Study of Aspirin in Patients With Vestibular Schwannoma
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
- Conditions
- Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
- Trial name
- NCT03079999
- Testing
- Aspirin
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
LGCMN, Large and Giant Congenital Melanocytic Nevi
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
Background: Large and giant congenital melanocytic nevi (LGCMN) are dark birthmarks (moles). They can grow to 8 inches or more across.
- Conditions
- LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor
- Trial name
- NCT07891286
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Malignancies, Ependymoma
Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma
This is a phase I study to investigate the safety and pharmacokinetics of weekly 5-fluorouracil (5-FU) administered as a bolus dose in children and young adults with recurrent or refractory ependymoma.
- Trial name
- SJREFU (NCT01498783)
- Testing
- 5-fluorouracil
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial
This phase I trial investigates the side effects and determines the best dose of an immune cell therapy called GD2CART, as well as how well it works in treating patients with osteosarcoma or neuroblastoma that has come back…
- Conditions
- Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma
- Trial name
- NCT04539366
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Astrocytic Tumors
Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma
This study looked at a type of brain tumor called astrocytoma and how specific genetic changes like IDH mutations affect patients outcomes.
- Conditions
- Astrocytoma, Astrocytic Tumors, Astrocytoma of Brain
- Trial name
- NCT06620926
- Testing
- IDH mutant-type, IDH wild-type
- Where
- Egypt
- Volunteers
- 811 people
- Sponsor
- asmaa salama ibrahim
Childhood Brain Tumors
Antineoplaston Therapy in Treating Children With Brain Tumors
RATIONALE: Current therapies for childhood brain tumors provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of childhood brain tumors.
- Trial name
- NCT00003458
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Burzynski Research Institute
SCLC, Malignant Melanoma
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA…
- Conditions
- SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
- Trial name
- NCT05130255
- Testing
- GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi), GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi), GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Y-mAbs Therapeutics
Melanoma (Skin), Skin Cancer
Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App
This study aims to examine the isolated effect of leaderboards (scoreboards) and daily training motivation on dermatology skill acquisition and training engagement within a gamified dermoscopy training platform.
- Trial name
- NCT06254547
- Testing
- Daily updated ranking on leaderboard, Daily motivational message
- Where
- Denmark
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital